HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.